Table 3.
Baseline characteristics after propensity score matching
| Variables | PCP negative (n = 118) |
PCP positive (n = 68) |
P |
|---|---|---|---|
| Age (years) | 46.7 ± 14.6 | 48.3 ± 14.4 | 0.504 |
| Female (%) | 21.8 | 23.5 | 0.792 |
| Body mass index (kg/m2) | 22.5 ± 3.4 | 22.6 ± 2.6 | 0.509 |
| Donor type (%) | 0.447 | ||
| Living | 64.5 | 58.8 | |
| Deceased | 35.5 | 41.2 | 0.846 |
| Standard criteria donor | 24.5 | 29.4 | |
| Expanded criteria donor | 10.9 | 11.8 | |
| Pre-transplant dialysis (%) | 0.102 | ||
| Preemptive | 15.3 | 22.1 | |
| Hemodialysis | 68.6 | 47.1 | |
| Peritoneal dialysis | 16.1 | 30.9 | |
| Duration of dialysis (months) | 47.4 ± 52.1 | 44.1 ± 54.0 | 0.704 |
| Re-transplantation | 6.8 | 7.4 | 0.883 |
| ABO-incompatible (%) | 7.6 | 19.1 | 0.019 |
| HLA mismatch (numbers) | 3.1 ± 1.5 | 3.1 ± 1.7 | 0.915 |
| Calcineurin inhibitor (%) | 0.349 | ||
| None | 2.5 | 5.9 | |
| Cyclosporine | 13.6 | 8.8 | |
| Tacrolimus | 83.9 | 85.3 | |
| Induction regimen (%) | 0.108 | ||
| None | 15.3 | 7.4 | |
| Basliximab | 82.2 | 92.6 | |
| Antithymocyte globulin | 2.5 | 0 | |
| Desensitization (%) | 11.0 | 22.1 | 0.043 |
| Diabetes mellitus (%) | 20.3 | 22.1 | 0.781 |
| Hypertension (%) | 94.1 | 98.5 | 0.149 |
| DMN for kidney failure (%) | 19.5 | 19.1 | 0.950 |
| Positivity for CMV (%) | 57.6 | 60.3 | 0.722 |
| Oral prophylactic antibiotics (%) | 14.4 | 10.3 | 0.420 |
| Acute T cell-mediated rejection (%) | 66.9 | 61.8 | 0.475 |
| Acute antibody-mediated rejection (%) | 9.3 | 11.8 | 0.596 |
| Interstitial fibrosis and tubular atrophy (%) | 37.3 | 42.6 | 0.471 |
| De novo donor-specific antibody (%) | 12.7 | 11.8 | 0.850 |
Comparisons were evaluated between PCP-negative and PCP-positive groups
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HLA human leukocyte antigen, DMN diabetic nephropathy, CMV cytomegalovirus